Malcolm Rivera
India's in-vitro diagnostics (IVD) market is experiencing significant growth, driven by a high disease burden, including diabetes, cardiovascular disease, cancer, and infectious diseases. The IVD market in India is expected to reach USD 2.51 billion by 2030, growing at a CAGR of 6.58%. The COVID-19 pandemic significantly impacted the market, increasing the demand for molecular diagnostics and rapid diagnostic development. India's growing middle class, increasing healthcare expenditure, and customer preference for early disease detection also contribute to the market's expansion. The rise in chronic diseases, an ageing population, and the adoption of innovative technologies further enhance the growth of the IVD market in India.
| Characteristics | Values |
|---|---|
| Market Size in 2023 | USD 394.76 million |
| Projected Market Size in 2030 | USD 2.51 billion |
| CAGR from 2024 to 2030 | 4.6% |
| Major Drivers | Rising infectious disease testing, chronic disease burden, robust lab network, increasing healthcare expenditure, growing middle class, rising geriatric population, and increasing prevalence of chronic diseases |
| Major Disorders | Infectious diseases, sexually transmitted diseases, HIV/AIDS, ventilator-acquired pneumonia, tuberculosis, hospital-acquired infections, diabetes, cardiovascular diseases, cancer, autoimmune diseases, nephrological diseases, gastrointestinal diseases |
| Major Companies | Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche AG, Transasia Bio-Medicals Ltd, Roche Diagnostics, Siemens Healthineers, Mindray, Sysmex, Autobio, Agappe, Mylab Discovery Solutions, Sanskritech, Cipla, Thermo Fisher Scientific |
Explore related products
Infectious diseases
In addition to COVID-19, other infectious diseases such as sexually transmitted diseases, HIV/AIDS, ventilator-acquired pneumonia, tuberculosis, and hospital-acquired infections contribute to the IVD market in India. The rising incidence of infectious diseases and the need for early detection and prevention drive the market growth. The adoption of point-of-care testing, such as POC testing, helps bring testing closer to patients and expedites diagnoses and treatment.
The IVD market in India is expected to grow due to the increasing prevalence of chronic diseases, an ageing population, and the demand for early detection and prevention. The rise in diseases such as diabetes, cardiovascular diseases, and cancer contributes to the market growth. The increasing incidence of infectious diseases and the adoption of molecular diagnostics and point-of-care testing further drive the market.
The Indian government's initiatives, such as the "Make in India" program, also support the IVD market by helping manufacturers meet the demand for medical equipment and enhancing the country's manufacturing capabilities. The presence of a robust network of laboratories and accelerating economic development further contribute to the growth of the IVD market in India.
India's Constitution: A Book of Laws and Rights
You may want to see also
Chronic conditions
India's in vitro diagnostics (IVD) market is experiencing significant growth, driven by a range of factors, including the increasing prevalence of chronic conditions. The country's growing middle class and rising healthcare expenditure are also contributing to the expanding IVD market.
The ageing population in India is another factor contributing to the rise in chronic conditions. The increasing geriatric population, coupled with the penetration of chronic diseases, requires effective and reliable diagnostic tests, further increasing the demand for IVD.
The adoption of point-of-care testing and molecular diagnostics are key trends in the Indian market. The shift towards point-of-care testing brings testing closer to patients and expedites diagnoses and subsequent treatment. The increasing adoption of self-blood glucose monitoring devices, for instance, has been a crucial market driver, with diabetes constituting a significant portion of the global IVD market.
Regulatory challenges, reimbursement issues, and the affordability of high-end devices remain limitations to the market growth. However, the Indian government's initiatives, such as the "Make in India" program, are helping to meet the demand for medical equipment and enhance manufacturing capabilities. The Indian IVD market is expected to continue its lucrative growth and rapid innovation, with advancements in molecular diagnostics and new product launches.
Understanding Simple Majorities in Indian Constitution
You may want to see also
Cancer
The trend towards personalized medicine, where treatments are tailored to individual genetic profiles, is also a significant driver for the IVD market in India. Molecular diagnostics, a key component of personalized medicine, plays a crucial role in predicting disease risk, selecting targeted therapies, and monitoring patient responses. This trend has driven healthcare providers and researchers to invest in molecular diagnostics, boosting demand for specialized tests, particularly in the field of oncology.
The Indian IVD market is also characterized by rapid innovation and new product launches. For example, in March 2023, NeoGenomics, Inc., a leading provider of oncology testing, expanded its next-generation sequencing (NGS) portfolio with the launch of multiple tests for solid tumor cancers and myeloid neoplasms. Additionally, in October 2023, the Central Drugs Standard Control Organization approved NexCAR19, India's first CAR-T cell therapy for cancer patients.
The increasing geriatric population in India, coupled with the rising prevalence of chronic diseases, further contributes to the demand for effective and reliable diagnostic tests, including those for cancer. The Indian government's initiatives, such as "Make in India," also support the IVD market by helping manufacturers meet the demand for medical equipment and enhancing the country's manufacturing capabilities.
Overall, the Indian IVD market is expected to continue its significant growth, with a projected value of USD 1.82 billion in 2025 and a compound annual growth rate (CAGR) of 6.58% from 2024 to 2030. The market is driven by technological advancements, increasing healthcare awareness, and the rising demand for early diagnosis and prevention of diseases, including cancer.
Indie Film: Defining Characteristics and Creative Freedom
You may want to see also
Explore related products
Cardiovascular diseases
India's growing middle class and increasing healthcare expenditure are driving demand for In Vitro Diagnostics in the country. The market was valued at USD 394.76 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 4.6% from 2024 to 2030. This growth is attributed to several factors, including the increasing incidence of chronic and infectious diseases, the need for early diagnosis, and government initiatives to improve healthcare infrastructure.
The demand for cardiovascular disease therapeutics in India is on the rise, with the market projected to grow from $2.95 billion in 2022 to $6.44 billion in 2030, representing a CAGR of 10.22%. This growth is driven by the increasing prevalence of hypertension and other CVDs, as well as the need for advanced therapeutics such as statins, ACE inhibitors, and beta-blockers. However, the high cost of treatment and limited access to medical institutions and skilled healthcare workers in certain areas of India pose challenges to the market's growth.
The Indian government has implemented initiatives such as the Ayushman Bharat scheme to provide low-income households with access to healthcare and reimbursement policies for CVD-related treatments like angioplasty and bypass surgery. These initiatives, along with advancements in molecular diagnostics and new product launches, are expected to further drive the growth of the IVD market in India, particularly in the coagulation segment, which is projected to grow rapidly due to the increasing prevalence of CVDs and blood-related disorders.
Overall, the increasing incidence of CVDs, coupled with the need for early diagnosis and effective therapeutics, is driving the growth of the IVD market in India. The market is expected to continue its lucrative growth trajectory, fueled by innovation, rising purchasing power, and government initiatives to improve healthcare infrastructure and accessibility.
India's Constitution: Vital Features and Their Importance
You may want to see also
Diabetes
India's in vitro diagnostics (IVD) market is experiencing significant growth, driven by the country's growing middle class, increasing healthcare expenditure, and the presence of purchasing power. The rise in chronic diseases, such as diabetes, is a critical driver of the IVD market in the region.
The Indian diabetes market is also witnessing substantial growth, with an expected value of USD 15.4 billion by 2033, up from USD 4.8 billion in 2024, representing a CAGR of 13.1%. This growth is attributed to several factors, including the increasing adoption of unhealthy lifestyle habits, particularly among the younger and working populations. These habits include the consumption of fast food, processed food, and packaged food products, sleep deprivation, physical inactivity, excessive stress, and regular drinking and smoking. As a result, obesity and diabetes are on the rise in India, with a growing demand for insulin and oral antidiabetic drugs.
The Indian government is taking initiatives to address this growing health concern by implementing cost-effective measures to increase the availability of anti-diabetic treatments, especially in rural areas. These measures include patient education programs and updating medical professionals on the latest developments in diabetes management, leading to increased diagnosis and treatment rates.
The market for insulin drugs in India is dominated by a few major players, including Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The competition among these companies is intense, with each striving to develop new drugs and offer them at competitive prices. The market for oral antidiabetic drugs is more fragmented, with a higher volume of new entrants in the generic market.
The increasing prevalence of diabetes in India, coupled with the demand for early detection and prevention of the disease, is expected to further drive the growth of the IVD market in the country.
Socialism in India's Constitution: A Fundamental Principle?
You may want to see also
Frequently asked questions
Infectious diseases, such as COVID-19, HIV/AIDS, and tuberculosis, constitute the major IVD market in India.
The growth of the IVD market in India is also driven by the increasing prevalence of chronic diseases, such as diabetes, cardiovascular diseases, and cancer. The adoption of point-of-care testing and molecular diagnostics are also key trends in the market.
The COVID-19 pandemic significantly impacted the IVD market in India, increasing the demand for molecular diagnostics and rapid diagnostic development.
Some of the challenges faced by the IVD market in India include the high pricing of tests, the lack of standardized pricing across laboratories, and the lack of product standardization.
